Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Change in blood brain barrier permeability over three months for the treatment group compared to the control group.
We will measure the change in blood brain barrier permeability with dynamic contrast enhanced MRI from baseline to three months. We will compare the change in permeability for a group of CCM patients placed on statin medication (treatment group) with a group of CCM patients not on statin medication (control group).
Baseline, Three Months
Leslie A Morrison, MD
University of New Mexico
United States: Institutional Review Board
|University of New Mexico Health Sciences Center||Albuquerque, New Mexico 87131|